Vectura has seven revenue generating lead inhaled in-market assets.


Marketed products

flutiform® (EU & ROW) - ICS-LABA (Anti-inflammatory and bronchodilator)

flutiform® (EU & ROW) - ICS-LABA (Anti-inflammatory and bronchodilator)

(fluticasone propionate / formoterol fumarate dihydrate)

  • Primary indication: Asthma
  • PartnersMundipharma (EU) and Kyorin (Japan)
  • DescriptionA fixed-dose combination therapy for the regular treatment of asthma in patients aged 12 years and over delivered in a pMDI
  • HistoryDeveloped by Vectura(1) using inhalation formulation expertise and proprietary technology. Vectura took the product from initial concept through to commercial manufacture

Ultibro® Breezhaler® (EU & ROW) - LAMA-LABA (Dual bronchodilator)

Ultibro® Breezhaler® (EU & ROW) - LAMA-LABA (Dual bronchodilator)

(indacaterol/glycopyrronium bromide)

  • Primary indication: COPD
  • Partner: Novartis
  • Description: A novel, once-daily fixed dose, dual bronchodilator approved in the EU as a maintenance bronchodilator treatment for adult patients with COPD
  • History: Glycopyrronium bromide was exclusively licenced to Novartis in April 2005 by Vectura and our co-development partner Sosei Group Corporation

Seebri® Breezhaler® (EU & ROW) - LAMA (Bronchodilator)

Seebri® Breezhaler® (EU & ROW) - LAMA (Bronchodilator)

(glycopyrronium bromide)

  • Primary indication: COPD
  • Partner: Novartis
  • DescriptionA novel, once-daily fixed dose, maintenance bronchodilator treatment for adult patients with COPD
  • HistoryGlycopyrronium bromide was exclusively licenced to Novartis in April 2005 by Vectura and our co-development partner Sosei Group Corporation

AirFluSal® Forspiro® (EU & ROW) - ICS-LABA (Anti-inflammatory and bronchodilator)

AirFluSal® Forspiro® (EU & ROW) - ICS-LABA (Anti-inflammatory and bronchodilator)

(fluticasone propionate/salmeterol)

  • Primary indicationAsthma/COPD
  • Partner: Sandoz
  • DescriptionInnovative inhaler with inhaled combination therapy for asthma and/or COPD
  • HistoryVectura initially developed the product and created the design of the innovative inhaler before licensing the asset to Sandoz in 2006

(1) As legacy Skyepharma part of the business

Photos of Seebri® Breezhaler® and Ultibro® Breezhaler® courtesy of Novartis AG. Ultibro®, Seebri®, Breezhaler®, AirFluSal® and Forspiro® are registered trade marks of Novartis AG.

 


Licenced products

Anoro® Ellipta® - LAMA-LABA (Dual bronchodilator)

Anoro® Ellipta® - LAMA-LABA (Dual bronchodilator)

(umeclidinium/vilanterol)

  • Primary indication: COPD
  • Technology licencee: GSK
  • Description: A multi-dose dry powder inhaler containing an anticholinergic, umeclidinium, and a long-acting bronchodilator, vilanterol, formulated by GSK using proprietary Vectura technology

Relvar® Ellipta®/Breo® Ellipta® - ICS-LABA (Anti-inflammatory and bronchodilator)

Relvar® Ellipta®/Breo® Ellipta® - ICS-LABA (Anti-inflammatory and bronchodilator)

(fluticasone furoate/vilanterol)

  • Primary indication: Asthma/COPD
  • Technology licencee: GSK
  • DescriptionA multi-dose dry powder inhaler containing a steroid, fluticasone furoate, and a long-acting bronchodilator, vilanterol, formulated by GSK using proprietary Vectura technology

Incruse® Ellipta® - LAMA (Bronchodilator)

Incruse® Ellipta® - LAMA (Bronchodilator)

(umeclidinium)

  • Primary indication: COPD
  • Technology licencee: GSK
  • Description: A multi-dose dry powder inhaler containing an anticholinergic, umeclidinium, formulated by GSK using proprietary Vectura technology

Anoro® Ellipta®, Relvar® Ellipta®/Breo® Ellipta® and Incruse® Ellipta® are registered trade marks of GSK, photos courtesy of GSK.

Until the end of July 2016, the Group also earned royalties from GSK under a legacy Vectura agreement, capped at £13 million in any calendar year. In July, Vectura announced that it has initiated legal proceedings against GSK in the US following GSK's decision not to extend the term of its legacy agreement with Vectura beyond 31 July 2016, by licensing additional patent families under the terms of the 2010 option-to-licence patent agreement between the parties. Whilst Vectura intends to enforce its patent rights to the fullest extent it remains open to finding a mutually acceptable solution in order to avoid costs and potential uncertainty. Until the outcome of the litigation is known, or a compromise is reached, the Group is not reflecting the receipt of further income from GSK in relation to the patent rights covered by the expired 2010 option-to license patent agreement.


 History

We have licence agreements with GSK for our dry powder formulation technology used in the above products.